Chronic Kidney Disease in Diabetes

Canadian Journal of Diabetes

Volumn 42, Issue , 2018, Pages S201-S209

  McFarlane, Philip ^a   Cherney, David ^a   Gilbert, Richard E ^a   Senior, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN INHIBITOR;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CANADA; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HUMAN; PRACTICE GUIDELINE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SCREENING; COMPLICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; STANDARDS;

DIABETES MELLITUS, TYPE 2; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85044754850     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2017.11.004     Document Type: Article

References (121)

1. Warram, J.H., Gearin, G., Laffel, L., et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7 (1996), 930–937.
2. Reenders, K., de Nobel, E., van den Hoogen, H.J., et al. Diabetes and its long-term complications in general practice: A survey in a well-defined population. Fam Pract 10 (1993), 169–172.
3. Weir, M.R., Albuminuria predicting outcome in diabetes: Incidence of microalbuminuria in Asia-Pacific Rim. Kidney Int Suppl, 2004, S38–S39.
4. Canadian Institute for Health Information (CIHI), Canadian organ replacement register annual report: Treatment of end-stage organ failure in Canada, 2000 to 2009. 2011, CIHI, Ottawa (ON).
5. Foley, R.N., Parfrey, P.S., Sarnak, M.J., Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (1998), S112–S119.
6. Bell, C.M., Chapman, R.H., Stone, P.W., et al. An off-the-shelf help list: A comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making 21 (2001), 288–294.
7. Mazzucco, G., Bertani, T., Fortunato, M., et al. Different patterns of renal damage in type 2 diabetes mellitus: A multicentric study on 393 biopsies. Am J Kidney Dis 39 (2002), 713–720.
8. Gambara, V., Mecca, G., Remuzzi, G., et al. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol 3 (1993), 1458–1466.
9. Mathiesen, E.R., Ronn, B., Storm, B., et al. The natural course of microalbuminuria in insulin-dependent diabetes: A 10-year prospective study. Diabet Med 12 (1995), 482–487.
10. Lemley, K.V., Abdullah, I., Myers, B.D., et al. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 58 (2000), 1228–1237.
11. de Boer, I.H., Sibley, S.D., Kestenbaum, B., et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 18 (2007), 235–243.
12. MacIsaac, R.J., Ekinci, E.I., Jerums, G., Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 63 (2014), S39–S62.
13. Gall, M.A., Nielsen, F.S., Smidt, U.M., et al. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 36 (1993), 1071–1078.
14. Jacobsen, P., Rossing, K., Tarnow, L., et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl 71 (1999), S101–S105.
15. Stevens, L.A., Coresh, J., Greene, T., et al. Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med 354 (2006), 2473–2483.
16. Hasslacher, C., Ritz, E., Wahl, P., et al. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 4 (1989), 859–863.
17. Biesenbach, G., Bodlaj, G., Pieringer, H., et al. Clinical versus histological diagnosis of diabetic nephropathy–is renal biopsy required in type 2 diabetic patients with renal disease?. QJM 104 (2011), 771–774.
18. Middleton, R.J., Foley, R.N., Hegarty, J., et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 21 (2006), 88–92.
19. Molitch, M.E., Steffes, M., Sun, W., et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 33 (2010), 1536–1543.
20. Macisaac, R.J., Jerums, G., Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 20 (2011), 246–257.
21. Ruggenenti, P., Gambara, V., Perna, A., et al. The nephropathy of non-insulin-dependent diabetes: Predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 9 (1998), 2336–2343.
22. VenkataRaman, T.V., Knickerbocker, F., Sheldon, C.V., Unusual causes of renal failure in diabetics: Two case studies. J Okla State Med Assoc 83 (1990), 164–168.
23. Anonymous, Clinical path conference. Unusual renal complications in diabetes mellitus. Minn Med 50 (1967), 387–393.
24. Amoah, E., Glickman, J.L., Malchoff, C.D., et al. Clinical identification of nondiabetic renal disease in diabetic patients with type I and type II disease presenting with renal dysfunction. Am J Nephrol 8 (1988), 204–211.
25. El-Asrar, A.M., Al-Rubeaan, K.A., Al-Amro, S.A., et al. Retinopathy as a predictor of other diabetic complications. Int Ophthalmol 24 (2001), 1–11.
26. Ballard, D.J., Humphrey, L.L., Melton, L.J. 3rd, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 37 (1988), 405–412.
27. Winaver, J., Teredesai, P., Feldman, H.A., et al. Diabetic nephropathy as the mode of presentation of diabetes mellitus. Metabolism 28 (1979), 1023–1030.
28. Ahn, C.W., Song, Y.D., Kim, J.H., et al. The validity of random urine specimen albumin measurement as a screening test for diabetic nephropathy. Yonsei Med J 40 (1999), 40–45.
29. Kouri, T.T., Viikari, J.S., Mattila, K.S., et al. Microalbuminuria. Invalidity of simple concentration-based screening tests for early nephropathy due to urinary volumes of diabetic patients. Diabetes Care 14 (1991), 591–593.
30. Rodby, R.A., Rohde, R.D., Sharon, Z., et al. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 26 (1995), 904–909.
31. Chaiken, R.L., Khawaja, R., Bard, M., et al. Utility of untimed urinary albumin measurements in assessing albuminuria in black NIDDM subjects. Diabetes Care 20 (1997), 709–713.
32. Bakker, A.J., Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 22 (1999), 307–313.
33. Huttunen, N.P., Kaar, M., Puukka, R., et al. Exercise-induced proteinuria in children and adolescents with type 1 (insulin dependent) diabetes. Diabetologia 21 (1981), 495–497.
34. Solling, J., Solling, K., Mogensen, C.E., Patterns of proteinuria and circulating immune complexes in febrile patients. Acta Med Scand 212 (1982), 167–169.
35. Ritz, E., Nephropathy in type 2 diabetes. J Intern Med 245 (1999), 111–126.
36. Wiseman, M., Viberti, G., Mackintosh, D., et al. Glycaemia, arterial pressure and micro-albuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 26 (1984), 401–405.
37. Ravid, M., Savin, H., Lang, R., et al. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients. Arch Intern Med 152 (1992), 1225–1229.
38. Gault, M.H., Longerich, L.L., Harnett, J.D., et al. Predicting glomerular function from adjusted serum creatinine. Nephron 62 (1992), 249–256.
39. Bending, J.J., Keen, H., Viberti, G.C., Creatinine is a poor marker of renal failure. Diabet Med 2 (1985), 65–66.
40. Shemesh, O., Golbetz, H., Kriss, J.P., et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28 (1985), 830–838.
41. Levey, A.S., Bosch, J.P., Lewis, J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999), 461–470.
42. Levey, A.S., Stevens, L.A., Schmid, C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
43. Poggio, E.D., Wang, X., Greene, T., et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16 (2005), 459–466.
44. Wang, P.H., Lau, J., Chalmers, T.C., Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 341 (1993), 1306–1309.
45. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47 (1995), 1703–1720.
46. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
47. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Lachin, J.M., Genuth, S., et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342 (2000), 381–389.
48. Shichiri, M., Kishikawa, H., Ohkubo, Y., et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23:Suppl. 2 (2000), B21–B29.
49. Zoungas, S., Arima, H., Gerstein, H.C., et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: A meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5 (2017), 431–437.
50. The Diabetes Control Complications Trial Research Group, Nathan, D.M., et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
51. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998), 703–713.
52. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
53. ADVANCE Collaborative Group, Patel, A., MacMahon, S., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
54. Ismail-Beigi, F., Craven, T., Banerji, M.A., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 376 (2010), 419–430.
55. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
56. Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ, 343, 2011, d4169.
57. Pathak, R.D., Schroeder, E.B., Seaquist, E.R., et al. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005–2011. Diabetes Care 39 (2016), 363–370.
58. Yun, J.-S., Ko, S.-H., Ko, S.-H., et al. Presence of macroalbuminuria predicts severe hypoglycemia in patients with type 2 diabetes: A 10-year follow-up study. Diabetes Care 36 (2013), 1283–1289.
59. Peacock, T.P., Shihabi, Z.K., Bleyer, A.J., et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 73 (2008), 1062–1068.
60. Ng, J.M., Cooke, M., Bhandari, S., et al. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care 33 (2010), 2310–2313.
61. Schrier, R.W., Estacio, R.O., Mehler, P.S., et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: A summary of the ABCD trial. Nat Clin Pract Nephrol 3 (2007), 428–438.
62. de Galan, B.E., Perkovic, V., Ninomiya, T., et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 20 (2009), 883–892.
63. Maki, D.D., Ma, J.Z., Louis, T.A., et al. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155 (1995), 1073–1080.
64. Voyaki, S.M., Staessen, J.A., Thijs, L., et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 19 (2001), 511–519.
65. Schrier, R.W., Estacio, R.O., Esler, A., et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002), 1086–1097.
66. Lewis, J.B., Berl, T., Bain, R.P., et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 34 (1999), 809–817.
67. ACCORD Study Group, Cushman, W.C., Evans, G.W., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
68. Ruggenenti, P., Fassi, A., Ilieva, A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004), 1941–1951.
69. Strippoli, G.F., Craig, M.C., Schena, F.P., et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 17 (2006), S153–S155.
70. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349 (1997), 1787–1792.
71. Bilous, R., Chaturvedi, N., Sjolie, A.K., et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials. Ann Intern Med 151 (2009), 11–20 w3-4.
72. Mauer, M., Zinman, B., Gardiner, R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361 (2009), 40–51.
73. Barnett, A.H., Bain, S.C., Bouter, P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 (2004), 1952–1961.
74. The Heart Outcomes Prevention Evaluation Study Investigators, Yusuf, S., Sleight, P., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000), 145–153.
75. Lewis, E.J., Hunsicker, L.G., Bain, R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993), 1456–1462.
76. Andersen, S., Tarnow, L., Rossing, P., et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57 (2000), 601–606.
77. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
78. Brenner, B.M., Cooper, M.E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
79. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001), 870–878.
80. Viberti, G., Wheeldon, N.M., MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106 (2002), 672–678.
81. Laffel, L.M., McGill, J.B., Gans, D.J., The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 99 (1995), 497–504.
82. Mathiesen, E.R., Hommel, E., Giese, J., et al. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303 (1991), 81–87.
83. Jerums, G., Allen, T.J., Campbell, D.J., et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 37 (2001), 890–899.
84. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134 (2001), 370–379.
85. Ravid, M., Savin, H., Jutrin, I., et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118 (1993), 577–581.
86. Mathiesen, E.R., Hommel, E., Hansen, H.P., et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 319 (1999), 24–25.
87. Ruggenenti, P., Perna, A., Gherardi, G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). ramipril efficacy in nephropathy. Lancet 352 (1998), 1252–1256.
88. Maschio, G., Alberti, D., Locatelli, F., et al. Angiotensin-converting enzyme inhibitors and kidney protection: The AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 33 Suppl 1 (1999), S16–S20 discussion S41-3.
89. Shoda, J., Kanno, Y., Suzuki, H., A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med 45 (2006), 193–198.
90. Hou, F.F., Xie, D., Zhang, X., et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 18 (2007), 1889–1898.
91. Jacobsen, P., Parving, H.H., Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. Kidney Int Suppl, 2004, S108–S110.
92. Burgess, E., Muirhead, N., Rene de Cotret, P., et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 20 (2009), 893–900.
93. Epstein, M., Williams, G.H., Weinberger, M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1 (2006), 940–951.
94. Parving, H.H., Persson, F., Lewis, J.B., et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358 (2008), 2433–2446.
95. Tobe, S.W., Clase, C.M., Gao, P., et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: Results from the ONTARGET and TRANSCEND studies. Circulation 123 (2011), 1098–1107.
96. Patel, A. ADVANCE Collaborative Group, MacMahon, S., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 370 (2007), 829–840.
97. Mann, J.F., Schmieder, R.E., McQueen, M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008), 547–553.
98. Parving, H.H., Brenner, B.M., McMurray, J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
99. Fried, L.F., Emanuele, N., Zhang, J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
100. Gerstein, H.C., Mann, J.F., Yi, Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001), 421–426.
101. Gaede, P., Vedel, P., Larsen, N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
102. Gaede, P., Vedel, P., Parving, H.H., et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 353 (1999), 617–622.
103. Gaede, P., Lund-Andersen, H., Parving, H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008), 580–591.
104. Levey, A.S., Coresh, J., Chronic kidney disease. Lancet 379 (2012), 165–180.
105. Levey, A.S., Eckardt, K.U., Tsukamoto, Y., et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67 (2005), 2089–2100.
106. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
107. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
108. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
109. Mann, J.F.E., Ørsted, D.D., Brown-Frandsen, K., et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 839–848.
110. Bakris, G.L., Weir, M.R., Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?. Arch Intern Med 160 (2000), 685–693.
111. Reams, G.P., Bauer, J.H., Gaddy, P., Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Effect on blood pressure, renal function, and the renin-angiotensin-aldosterone system. Hypertension 8 (1986), 290–297.
112. Franklin, S.S., Smith, R.D., Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 79 (1985), 14–23.
113. Miyamori, I., Yasuhara, S., Takeda, Y., et al. Effects of converting enzyme inhibition on split renal function in renovascular hypertension. Hypertension 8 (1986), 415–421.
114. Desai, A.S., Swedberg, K., McMurray, J.J., et al. Incidence and predictors of hyperkalemia in patients with heart failure: An analysis of the CHARM Program. J Am Coll Cardiol 50 (2007), 1959–1966.
115. Pitt, B., Bakris, G., Ruilope, L.M., et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118 (2008), 1643–1650.
116. Juurlink, D.N., Mamdani, M.M., Lee, D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004), 543–551.
117. Palmer, B.F., Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351 (2004), 585–592.
118. Cooper, W.O., Hernandez-Diaz, S., Arbogast, P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354 (2006), 2443–2451.
119. Levin, A., Mendelssohn, D., Care and referral of adult patients with reduced kidney function: Position paper from the Canadian Society of Nephrology. 2006, Canadian Society of Nephrology (CSN), Montreal, QC http://www.cdha.nshealth.ca/system/files/sites/131/documents/care-and-referral-adult-patients-reduced-kidney-function-csn-position-paper.pdf.
120. Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 6, 2009, e1000097.
121. Afkarian, M., Zelnick, L.R., Hall, Y.N., et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 316 (2016), 602–610.